Search research articles
Contact Us
Filters
Showing results (141-150 of 167) with videos related to
Page
of 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
William G Wierda, John N Allan, Tanya Siddiqi, et al.
The Lancet. Oncology
|
November 9, 2023
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Carsten U Niemann, Talha Munir, Carol Moreno, et al.
Annals of Hematology
|
January 20, 2017
Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial
Laura Magnano, Silvia Montoto, Eva González-Barca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2023
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
Talha Munir, Carol Moreno, Carolyn Owen, et al.
Bone Marrow Transplantation
|
December 20, 2017
Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT
Gwendolyn van Gorkom, Michel van Gelder, Dirk-Jan Eikema, et al.
Blood
|
April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Paul M Barr, Jennifer R Brown, Peter Hillmen, et al.
Cancer Research
|
August 31, 2014
CXM: a new tool for mapping breast cancer risk in the tumor microenvironment
Michael J Flister, Bradley T Endres, Nathan Rudemiller, et al.
American Journal of Hematology
|
April 7, 2017
Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance
Maria Joao Baptista, Isabel Granada, Mireia Morgades, et al.
Kidney International
|
January 29, 2024
Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine
Anna Reznichenko, Viji Nair, Sean Eddy, et al.
Eclinicalmedicine
|
June 6, 2024
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)
Pau Abrisqueta, Eva González-Barca, Christelle Ferrà, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 167) with videos related to
Sort By:
Page
of 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
William G Wierda, John N Allan, Tanya Siddiqi, et al.
The Lancet. Oncology
|
November 9, 2023
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Carsten U Niemann, Talha Munir, Carol Moreno, et al.
Annals of Hematology
|
January 20, 2017
Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial
Laura Magnano, Silvia Montoto, Eva González-Barca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2023
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
Talha Munir, Carol Moreno, Carolyn Owen, et al.
Bone Marrow Transplantation
|
December 20, 2017
Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT
Gwendolyn van Gorkom, Michel van Gelder, Dirk-Jan Eikema, et al.
Blood
|
April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Paul M Barr, Jennifer R Brown, Peter Hillmen, et al.
Cancer Research
|
August 31, 2014
CXM: a new tool for mapping breast cancer risk in the tumor microenvironment
Michael J Flister, Bradley T Endres, Nathan Rudemiller, et al.
American Journal of Hematology
|
April 7, 2017
Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance
Maria Joao Baptista, Isabel Granada, Mireia Morgades, et al.
Kidney International
|
January 29, 2024
Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine
Anna Reznichenko, Viji Nair, Sean Eddy, et al.
Eclinicalmedicine
|
June 6, 2024
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)
Pau Abrisqueta, Eva González-Barca, Christelle Ferrà, et al.
Page
of 17